New hemophilia shot shows early promise in small safety trial

NCT ID NCT05493631

Completed Disease control Sponsor: GC Biopharma Corp Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new drug called MG1113, given as a shot under the skin, in 15 adults with severe hemophilia A or B. The main goal was to check safety and how the drug moves through the body. Participants received multiple doses to see if the drug is well-tolerated. Since this is a Phase 1 trial, it is too early to know if MG1113 will effectively control bleeding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MG1113 (a biologic drug given as a shot under the skin)
What this could lead to: If successful, this could lead to a new treatment option for severe hemophilia that is easier to take than current therapies.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects. Much more research is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia hemophilia A severe hemophilia A severe hemophilia B

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHILIA

Contacts and locations

Locations

GC Biopharma Corp.

Yongin-si, Gyeonggi-do, 16924, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.